stockportfolio.pro
Halozyme Therapeutics, Inc. Total Debt 2009–2025
Halozyme Therapeutics, Inc. (HALO) annual total debt (short- plus long-term borrowings) by fiscal year, computed from SEC filings.
| Fiscal year | Total Debt | Change (YoY) |
|---|---|---|
| FY 2025 | $2.14B | +42.3% |
| FY 2024 | $1.51B | +0.4% |
| FY 2023 | $1.50B | -0.5% |
| FY 2022 | $1.51B | +91.3% |
| FY 2021 | $787.25M | — |
| FY 2020 | $0 | -100.0% |
| FY 2019 | $383.05M | +998.4% |
| FY 2018 | $34.87M | -72.1% |
| FY 2017 | $125.14M | -37.2% |
| FY 2016 | $199.23M | +612.3% |
| FY 2015 | $27.97M | -43.9% |
| FY 2014 | $49.86M | +0.2% |
| FY 2013 | $49.77M | +67.8% |
| FY 2012 | $29.66M | — |
| FY 2011 | $0 | — |
| FY 2010 | $0 | — |
| FY 2009 | $0 | — |
Source: Halozyme Therapeutics, Inc. SEC filings — balance sheet (10-K). Refreshed nightly.
See the full picture for Halozyme Therapeutics, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeHalozyme Therapeutics, Inc. — frequently asked questions
What is Halozyme Therapeutics, Inc.'s total debt (short- plus long-term borrowings)?
Halozyme Therapeutics, Inc. (HALO) reported total debt (short- plus long-term borrowings) of $2.14B for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Halozyme Therapeutics, Inc.'s official SEC filings (balance sheet (10-K)), refreshed nightly. Not investment advice.